Dr. Bekelman leads research programs in cancer health services and care quality, comparative effectiveness and delivery system and payment reform. His research integrates methods from the fields of epidemiology, clinical trials, health economics and public policy. Dr. Bekelman conducts research to examine the quality, comparative effectiveness, and costs of treatments for prostate, breast, lung and other prevalent cancers using registry, Medicare, and commercial payer administrative claims data and co-leads the multicenter PARTIQoL randomized trial, which compares patient-reported outcomes after proton therapy versus intensity-modulated radiotherapy (IMRT) for prostate cancer. Dr. Bekelman has received research funding from the National Cancer Institute, the American Cancer Society, and philanthropic sources. He did his undergraduate work at Princeton University in the Woodrow Wilson School of Public and International Affairs and his medical training at Yale University, Johns Hopkins, and Memorial Sloan Kettering Cancer Center. Previously, he was a management consultant at the Kalchas Group, advising senior executives of health care and insurance clients on corporate strategy. Dr. Bekelman also served as Special Assistant to the Under Secretary of Defense in the US Department of Defense. He is a board-certified radiation oncologist and practicing physician at the University of Pennsylvania Perelman School of Medicine.